Speak directly to the analyst to clarify any post sales queries you may have.
10% Free customizationThis report comes with 10% free customization, enabling you to add data that meets your specific business needs.
Rising Burden of Chronic Diseases
Increasing incidences and prevalence of chronic diseases such as cancer, hypertension, diabetes, heart strokes, and cardiovascular diseases (CVDs), among others, among the elderly population in the country, are bolstering the growth of the market. According to the European Society of Cardiology’s 2019 report, there are over 6 million new cases of CVD in the European Union (EU) and over 11 million in Europe in total every year. In addition, the increase in the proportion of older people who are aged 60 and more in the country is facilitating the growth of the market. This is because older people are more susceptible to chronic diseases due to rising age. For instance, according to Statista data of 2021, Europe has the largest proportion of the aging population at 19%, whereas Italy has the largest elderly population share with 23.5% of the total population.Growing Adoption of Advanced Technology
Rapid advancements in the tools and technology of the healthcare sector are projected to bolster the growth of the market. These advancements are made to make the devices more patient-friendly, accessible, and accurate. For instance, in 2021, Xeris Pharmaceuticals, Inc. obtained approval from the European Commission (EC) for an Ogluo (glucagon) pre-filled pen, which is used for the treatment of severe hypoglycemia in adults, adolescents, and children the age of 2 years and over with diabetes mellitus. In addition, several players are constantly researching new technologies and developing advanced drug-delivery devices. Therefore, propelling the growth of the market.Market Segmentation
Europe drug delivery devices market is segmented into the route of administration, device, end-user, company, and country. Based on the route of administration, the market is divided into oral drug delivery, injectable drug delivery, topical drug delivery, ocular drug delivery, pulmonary drug delivery, and others. Based on the device, the market is categorized into syringes, inhalers, patch pumps, and others. Based on end users, the market is bifurcated into hospitals & clinics, ambulatory surgery centers, and others. In terms of countries, the market is segmented into Germany, France, United Kingdom, Italy, Spain, Switzerland, Netherlands, Turkey, Sweden, and Belgium.Market Players
F. Hoffmann-La Roche Ltd, Antares Pharma, Novartis AG, 3M Company, Sulzer Ltd, Gerresheimer AG, Sanofi S.A., Johnson & Johnson Services, Inc., Bayer AG, and GlaxoSmithKline plc. are some of the leading companies operating in the market.Report Scope:
In this report, Europe drug delivery devices market has been segmented into the following categories, in addition to the industry trends, which have also been detailed below:Europe Drug Delivery Devices Market, By Route of Administration:
- Oral Drug Delivery
- Injectable Drug Deliver
- Topical Drug Delivery
- Ocular Drug Delivery
- Pulmonary Drug Delivery
- Others
Europe Drug Delivery Devices Market, By Device:
- Syringes
- Inhalers
- Patch Pumps
- Others
Europe Drug Delivery Devices Market, By End User:
- Hospitals & Clinics
- Ambulatory Surgery Centers
- Others
Europe Drug Delivery Devices Market, By Country:
- Germany
- France
- United Kingdom
- Italy
- Spain
- Switzerland
- Netherlands
- Turkey
- Sweden
- Belgium
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in Europe drug delivery devices market.Available Customizations:
With the given market data, the publisher offers customizations according to a company’s specific needs.This product will be delivered within 1-3 business days.
Table of Contents
Companies Mentioned
- F. Hoffmann-La Roche Ltd
- Antares Pharma
- Novartis AG
- 3M Company
- Sulzer Ltd
- Gerresheimer AG
- Sanofi S.A.
- Johnson & Johnson Services, Inc.
- Bayer AG
- GlaxoSmithKline plc